亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.

医学 吉西他滨 奥沙利铂 伦瓦提尼 内科学 肿瘤科 化疗 临床研究阶段 胃肠病学 外科 索拉非尼 癌症 肝细胞癌 结直肠癌
作者
Zhou Jian,Jia Fan,Guo–Ming Shi,Xiaoyong Huang,Dong Wu,Guo‐Huan Yang,Yuan Ji,Yi Chen,Fei Liang,Jia‐Cheng Lu,Ningling Ge,Hui‐Chuan Sun,Xiaowu Huang,Shuang‐Jian Qiu,Yifeng He,Xin‐Rong Yang,Yang Xu,Qiang Gao,Jian Sun
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:39 (15_suppl): 4094-4094 被引量:22
标识
DOI:10.1200/jco.2021.39.15_suppl.4094
摘要

4094 Background: The outcome of advanced intrahepatic cholangiocarcinoma (ICC) remains poor with current gemcitabine-based chemotherapy. This study is to evaluate the safety and efficacy of anti-PD1 agent toripalimab, lenvatinib in combination with oxaliplatin and gemcitabine (Gemox) chemotherapy. Methods: Locally advanced or metastatic ICC patients (pts) were given 240 mg toripalimab Q3W via intravenous (IV) infusion, 8 mg lenvatinib QD orally, and 1g/m² gemcitabine on Day 1 and Day 8, and 85 mg/m² oxaliplatin Q3W by IV for 6 cycles. The primary outcome was objective response rate (ORR), which was evaluated according to RECIST v1.1. Secondary outcomes included safety, progression-free survival (PFS) and overall survival (OS). Treatment would be terminated by confirmed disease progression, unacceptable toxicity, or voluntary withdrawal. Whole exome sequencing was performed on available tumor tissues and PD-L1 expression was determined by immunohistochemistry staining. Results: From May 2019 to Oct 2019, 30 pathologically-confirmed advanced ICC pts with a mean age of 56.5 (range, 25-73) years, including 11 women (37%), were enrolled at Zhongshan Hospital, Fudan University (one pt withdrawn). At the end of last follow-up (February 1, 2021), the ORR was 80% (24/30; 95% CI: 61.4%-92.3%), and disease control rate (DCR) was 93.3% (28/30; 95% CI:77.9%-99.2%). Median follow-up was 16.6 months. One pt achieved complete response (CR). Three pts with locally advanced disease were down-staged and then underwent resection. They remained disease-free survival at the end of last follow-up. 23 pts experienced disease progression and 12 pts (including one pt withdrawn) have died. The median PFS was 10.0 months and median duration of response (DOR) was 9.8 months. The median OS have not been reached. 12-months OS rate was 73.3% (95% CI: 57.5%-89.2%). No grade 5 adverse event (AE) was observed in present study. Grade 3 or 4 neutropenia and thrombocytopenia observed in 3 (10%) and 1 (3.3%) patient, respectively. Non-hematological toxic effects were jaundice (10 %), rash (6.7 %), proteinuria (6.7 %), increased AST level (3.3%), vomiting (3.3%), upper gastrointestinal hemorrhage (3.3%), sepsis (3.3%), gastrointestinal fistula (3.3%), adrenocortical insufficiency (3.3%), interstitial pneumonia (3.3%), and hyponatremia (3.3%). High ORR was significantly associated with positive PD-L1 expression ( p= 0.048) and DNA damage repair (DDR)-related mutations ( p= 0.022) in tumor samples. Conclusions: Gemox chemotherapy in combination with Anti-PD1 antibody Toripalimab and Lenvatinib provided remarkable efficacy with reasonable tolerability in advanced ICC patients. These findings warrant further validation in a large randomized clinical trial. Clinical trial information: NCT03951597.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ShowMaker应助风中绝悟采纳,获得20
18秒前
石鑫发布了新的文献求助20
20秒前
snah完成签到 ,获得积分10
35秒前
香蕉觅云应助石鑫采纳,获得10
35秒前
美丽觅夏完成签到 ,获得积分10
39秒前
Mistletoe完成签到 ,获得积分10
40秒前
赘婿应助xu采纳,获得10
43秒前
吃碗大米饭完成签到,获得积分10
44秒前
可爱的函函应助kirirto采纳,获得10
45秒前
48秒前
xj完成签到,获得积分10
50秒前
Mipe完成签到,获得积分10
58秒前
1分钟前
斯文败类应助科研通管家采纳,获得10
1分钟前
ding应助陳.采纳,获得10
1分钟前
健忘捕完成签到 ,获得积分10
1分钟前
1分钟前
陳.发布了新的文献求助10
1分钟前
Milton_z完成签到 ,获得积分10
1分钟前
1分钟前
liwang9301发布了新的文献求助10
1分钟前
石鑫发布了新的文献求助10
2分钟前
2分钟前
liwang9301完成签到,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
这个手刹不太灵完成签到 ,获得积分10
2分钟前
2分钟前
天才小熊猫完成签到,获得积分10
2分钟前
2分钟前
酷波er应助科研通管家采纳,获得10
3分钟前
3分钟前
开放的麦片完成签到,获得积分10
3分钟前
lizhoukan1完成签到,获得积分10
3分钟前
毛毛猫完成签到 ,获得积分10
3分钟前
cdu应助veggieg采纳,获得30
3分钟前
石鑫完成签到 ,获得积分10
3分钟前
舒服的幼荷完成签到,获得积分10
3分钟前
在路上完成签到 ,获得积分0
4分钟前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3150515
求助须知:如何正确求助?哪些是违规求助? 2801908
关于积分的说明 7845964
捐赠科研通 2459264
什么是DOI,文献DOI怎么找? 1309180
科研通“疑难数据库(出版商)”最低求助积分说明 628683
版权声明 601748